Company Email Format Management

Bridge Biotherapeutics, Inc.

Biotechnology Research United States 22 employees

Employees: 22
Contacts: 4
Emails: 4
Phones: 1

bridgebiorx.com LinkedIn Crunchbase

Bridge Biotherapeutics, Inc. Overview

Headquarters: United States
Website: bridgebiorx.com
Industry: Biotechnology Research
Employees: 22
Founded: 2015
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

About Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

Bridge Biotherapeutics, Inc. Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 1; 25.0% coverage

Bridge Biotherapeutics, Inc. Org Chart

Sample employees and titles

Name	Title	Location	Contact
Jason Jaesoon Kim		South Korea, Korea, Republic of	Email
James Jungkue Lee	Founder & CEO at Bridge	Seongnam, Gyeonggi, South Korea, Korea, Republic of	Email
Mikyoung Chang	Director, Scientific Affairs	Houston, Texas, United States	Email
B. Christopher Kim	EVP @ Bridge Bio, Advisor @ Curie.bio	Boston, Massachusetts, United States	Email Phone